NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
16 trialsNCT07078604 2026-03-12
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06434064 2026-03-02
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT07125183 2026-02-05
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
Phase 2 Recruiting
NCT04028063 2026-01-27
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Recruiting
NCT03618550 2025-12-02
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05029999 2025-08-13
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT06292286 2025-06-11
SCENIC
The University of Hong Kong
Phase NA Recruiting
NCT03971409 2025-05-02
InCITe
University of California, San Francisco
Phase 2 Recruiting
NCT05210374 2025-03-25
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT06791460 2025-03-18
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3 Recruiting
NCT05748834 2025-01-31
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT06102824 2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT05159193 2024-02-02
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05536102 2023-03-09
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting